This test helps highlight the specific foods linked to discomfort for improved gut health and overall well-being ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

J&J's Imaavy (nipocalimab-aahu) has received US Food and Drug Administration (FDA) approval for treating generalised ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...

University of Miami Miller School of Medicine researchers have identified molecular evidence linking human papillomavirus ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ...

A small case-control study found potential molecular evidence that links human papillomavirus (HPV) to thyroid eye disease ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Tetanus-diphtheriaa-acellular pertussis–inactivated polio virus vaccination during pregnancy is safe and boosts ...